7-105512131-A-G
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_019042.5(PUS7):c.-32-3587T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.33 ( 8091 hom., cov: 19)
Consequence
PUS7
NM_019042.5 intron
NM_019042.5 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -2.02
Publications
0 publications found
Genes affected
PUS7 (HGNC:26033): (pseudouridine synthase 7) Enables enzyme binding activity and pseudouridine synthase activity. Involved in several processes, including pseudouridine synthesis; regulation of hematopoietic stem cell differentiation; and regulation of mesoderm development. Located in nucleus. [provided by Alliance of Genome Resources, Apr 2022]
PUS7 Gene-Disease associations (from GenCC):
- intellectual developmental disorder with abnormal behavior, microcephaly, and short statureInheritance: AR Classification: STRONG, MODERATE Submitted by: G2P, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- syndromic intellectual disabilityInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-1.06).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.514 is higher than 0.05.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PUS7 | ENST00000469408.6 | c.-32-3587T>C | intron_variant | Intron 1 of 15 | 1 | NM_019042.5 | ENSP00000417402.1 | |||
| PUS7 | ENST00000356362.6 | c.-8-3611T>C | intron_variant | Intron 1 of 15 | 2 | ENSP00000348722.2 | ||||
| PUS7 | ENST00000481939.5 | n.-32-3587T>C | intron_variant | Intron 1 of 16 | 5 | ENSP00000418794.1 |
Frequencies
GnomAD3 genomes AF: 0.329 AC: 43258AN: 131566Hom.: 8062 Cov.: 19 show subpopulations
GnomAD3 genomes
AF:
AC:
43258
AN:
131566
Hom.:
Cov.:
19
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.329 AC: 43323AN: 131662Hom.: 8091 Cov.: 19 AF XY: 0.328 AC XY: 20705AN XY: 63066 show subpopulations
GnomAD4 genome
AF:
AC:
43323
AN:
131662
Hom.:
Cov.:
19
AF XY:
AC XY:
20705
AN XY:
63066
show subpopulations
African (AFR)
AF:
AC:
17944
AN:
34496
American (AMR)
AF:
AC:
3695
AN:
12382
Ashkenazi Jewish (ASJ)
AF:
AC:
922
AN:
3242
East Asian (EAS)
AF:
AC:
814
AN:
4380
South Asian (SAS)
AF:
AC:
1300
AN:
3708
European-Finnish (FIN)
AF:
AC:
1921
AN:
7896
Middle Eastern (MID)
AF:
AC:
56
AN:
268
European-Non Finnish (NFE)
AF:
AC:
15919
AN:
62756
Other (OTH)
AF:
AC:
546
AN:
1718
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.518
Heterozygous variant carriers
0
1241
2483
3724
4966
6207
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
420
840
1260
1680
2100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
816
AN:
3468
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.